Stock on Radar: Celyad SA (ADR) (NASDAQ:CYAD) Price Target ... - Rockville Register
During the past trading session, shares of Celyad SA (ADR) (NASDAQ:CYAD) traded +4.59%. Covering analysts are predicting the stock to move to $40.00 within the next year. Depending on the analyst, target price projections may differ widely. This target ...
Celyad SA (CYAD) Given $35.67 Consensus Target Price by ... - Transcript Daily
Celyad SA (NASDAQ:CYAD) traded up 1.99% during trading on Tuesday, hitting $41.47. The stock had a trading volume of 3,907 shares. The company's 50 day moving average is $34.10 and its 200 day moving average is $23.99. Celyad SA has a 52-week ...
The Zacks: Analysts Set $35.67 Target Price for Celyad SA (CYAD) - BangaloreWeekly
Shares of Celyad SA (NASDAQ:CYAD) traded down 4.15% during mid-day trading on Tuesday, reaching $37.38. The company had a trading volume of 4,526 shares. The company's market cap is $355.86 million. The firm's 50-day moving average price is ...altro »
Celyad : Bondit après signature d'un accord de licence avec Novartis - TradingSat
Celyad conserve pour sa part le droit d'octroyer d'autres licences à des tierces parties actives dans le développement de cellules CAR-T allogéniques. Celyad ne sera pas impliqué dans le développement des cellules CAR-T de Novartis. Celyad se concentre ...altro »
Celyad SA (CYAD) Given Consensus Rating of "Buy" by Brokerages - Sports Perspectives
Shares of Celyad SA (NASDAQ:CYAD) traded up 2.66% during mid-day trading on Tuesday, hitting $40.58. The stock had a trading volume of 786 shares. The stock's market capitalization is $386.32 million. The stock has a 50 day moving average of $33.69 ...
Celyad : Le titre flambe après l'obtention d'un label - TradingSat
La thérapie C-Cure de Celyad est une thérapie cellulaire parmi les plus avancées pour le traitement de l'insuffisance cardiaque. Les résultats de l'essai CHART-1 ont permis d'identifier une partie significative des patients qui a répondu favorablemeent ...altro »
Celyad SA (CYAD) Earns Media Impact Rating of 0.05 - Chaffey Breeze
Celyad SA (NASDAQ:CYAD) traded up 0.81% during trading on Monday, hitting $40.91. The stock had a trading volume of 945 shares. Celyad SA has a 52-week low of $16.31 and a 52-week high of $59.50. The firm's market cap is $389.46 million.
The Celyad SA (CYAD) Getting Favorable Media Coverage, Report ... - BangaloreWeekly
Shares of Celyad SA (NASDAQ:CYAD) traded up 2.66% during trading on Friday, hitting $40.58. 786 shares of the stock traded hands. The firm's market capitalization is $386.32 million. The firm has a 50-day moving average of $33.26 and a 200-day moving ...
Celyad SA (CYAD) Earning Positive Press Coverage, Study Finds - Transcript Daily
Shares of Celyad SA (NASDAQ:CYAD) traded down 1.91% during trading on Thursday, hitting $39.53. The stock had a trading volume of 1,636 shares. Celyad SA has a 12-month low of $16.31 and a 12-month high of $59.50. The stock's 50 day moving ...altro »
Form 6-K CELYAD SA For: May 23 - StreetInsider.com
In January, the U.S. Patent and Trade Office (USPTO) decided –for the third time – to uphold Celyad's U.S. Patent No. 9,181,527, relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a CAR. In March, the USPTO ...